# Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria

> **NCT04175704** · PHASE1 · UNKNOWN · sponsor: **United BioPharma** · enrollment: 32 (estimated)

## Conditions studied

- Chronic Idiopathic Urticaria

## Interventions

- **DRUG:** UB-221

## Key facts

- **NCT ID:** NCT04175704
- **Lead sponsor:** United BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12-30
- **Primary completion:** 2024-11-30
- **Final completion:** 2026-01-30
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2022-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04175704

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04175704, "Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04175704. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*